» Articles » PMID: 38928071

Hypertriglyceridemia: Molecular and Genetic Landscapes

Abstract

Lipid disorders represent one of the most worrisome cardiovascular risk factors. The focus on the impact of lipids on cardiac and vascular health usually concerns low-density lipoprotein cholesterol, while the role of triglycerides (TGs) is given poor attention. The literature provides data on the impact of higher plasma concentrations in TGs on the cardiovascular system and, therefore, on the outcomes and comorbidities of patients. The risk for coronary heart diseases varies from 57 to 76% in patients with hypertriglyceridemia. Specifically, the higher the plasma concentrations in TGs, the higher the incidence and prevalence of death, myocardial infarction, and stroke. Nevertheless, the metabolism of TGs and the exact physiopathologic mechanisms which try to explain the relationship between TGs and cardiovascular outcomes are not completely understood. The aims of this narrative review were as follows: to provide a comprehensive evaluation of the metabolism of triglycerides and a possible suggestion for understanding the targets for counteracting hypertriglyceridemia; to describe the inner physiopathological background for the relationship between vascular and cardiac damages derived from higher plasma concentrations in TGs; and to outline the need for promoting further insights in therapies for reducing TGs plasma levels.

References
1.
Haller J, Mintah I, Shihanian L, Stevis P, Buckler D, Alexa-Braun C . ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017; 58(6):1166-1173. PMC: 5454515. DOI: 10.1194/jlr.M075689. View

2.
Ginsberg H, Packard C, Chapman M, Boren J, Aguilar-Salinas C, Averna M . Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021; 42(47):4791-4806. PMC: 8670783. DOI: 10.1093/eurheartj/ehab551. View

3.
Hegele R, Ginsberg H, Chapman M, Nordestgaard B, Kuivenhoven J, Averna M . The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 2(8):655-66. PMC: 4201123. DOI: 10.1016/S2213-8587(13)70191-8. View

4.
De Villers-Lacasse A, Paquette M, Baass A, Bernard S . Non-alcoholic fatty liver disease in patients with chylomicronemia syndromes. J Clin Lipidol. 2023; 17(4):475-482. DOI: 10.1016/j.jacl.2023.05.096. View

5.
Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View